The first-in-human, dose-finding PROCLAIM-CX-072 trial to assess the antitumor activity and tolerability of the probody therapeutic CX-072 as monotherapy and in combination with ipilimumab or vemurafenib in solid advanced tumors and lymphomas

V. Boni; J. Garcia-Corbacho; J. Feliu; J. Wydmanski; Z. Horvath; I. Bondarenko; B. Irving; M. Will; E. G. E. de Vries; F. Thistlethwaite

The first-in-human, dose-finding PROCLAIM-CX-072 trial to assess the antitumor activity and tolerability of the probody therapeutic CX-072 as monotherapy and in combination with ipilimumab or vemurafenib in solid advanced tumors and lymphomas

V. Boni, J. Garcia-Corbacho, J. Feliu, J. Wydmanski, Z. Horvath, I. Bondarenko, B. Irving, M. Will, E. G. E. de Vries, F. Thistlethwaite

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Number of pages	2
Journal	Annals of Oncology
Volume	28
Publication status	Published - Sept-2017
Event	42nd European-Society-for-Medical-Oncology Congress (ESMO) - Madrid, Spain Duration: 8-Sept-2017 → 12-Sept-2017

Handle.net

Persistent link

Cite this

Boni, V., Garcia-Corbacho, J., Feliu, J., Wydmanski, J., Horvath, Z., Bondarenko, I., Irving, B., Will, M., de Vries, E. G. E., & Thistlethwaite, F. (2017). The first-in-human, dose-finding PROCLAIM-CX-072 trial to assess the antitumor activity and tolerability of the probody therapeutic CX-072 as monotherapy and in combination with ipilimumab or vemurafenib in solid advanced tumors and lymphomas. Annals of Oncology, 28.

@article{7a6195399aca4509af88309a707c6e2b,

title = "The first-in-human, dose-finding PROCLAIM-CX-072 trial to assess the antitumor activity and tolerability of the probody therapeutic CX-072 as monotherapy and in combination with ipilimumab or vemurafenib in solid advanced tumors and lymphomas",

author = "V. Boni and J. Garcia-Corbacho and J. Feliu and J. Wydmanski and Z. Horvath and I. Bondarenko and B. Irving and M. Will and {de Vries}, {E. G. E.} and F. Thistlethwaite",

year = "2017",

month = sep,

language = "English",

volume = "28",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

note = "42nd European-Society-for-Medical-Oncology Congress (ESMO) ; Conference date: 08-09-2017 Through 12-09-2017",

}

Boni, V, Garcia-Corbacho, J, Feliu, J, Wydmanski, J, Horvath, Z, Bondarenko, I, Irving, B, Will, M, de Vries, EGE & Thistlethwaite, F 2017, 'The first-in-human, dose-finding PROCLAIM-CX-072 trial to assess the antitumor activity and tolerability of the probody therapeutic CX-072 as monotherapy and in combination with ipilimumab or vemurafenib in solid advanced tumors and lymphomas', Annals of Oncology, vol. 28.

The first-in-human, dose-finding PROCLAIM-CX-072 trial to assess the antitumor activity and tolerability of the probody therapeutic CX-072 as monotherapy and in combination with ipilimumab or vemurafenib in solid advanced tumors and lymphomas. / Boni, V.; Garcia-Corbacho, J.; Feliu, J. et al.
In: Annals of Oncology, Vol. 28, 09.2017.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - The first-in-human, dose-finding PROCLAIM-CX-072 trial to assess the antitumor activity and tolerability of the probody therapeutic CX-072 as monotherapy and in combination with ipilimumab or vemurafenib in solid advanced tumors and lymphomas

AU - Boni, V.

AU - Garcia-Corbacho, J.

AU - Feliu, J.

AU - Wydmanski, J.

AU - Horvath, Z.

AU - Bondarenko, I.

AU - Irving, B.

AU - Will, M.

AU - de Vries, E. G. E.

AU - Thistlethwaite, F.

PY - 2017/9

Y1 - 2017/9

M3 - Meeting Abstract

SN - 0923-7534

VL - 28

JO - Annals of Oncology

JF - Annals of Oncology

T2 - 42nd European-Society-for-Medical-Oncology Congress (ESMO)

Y2 - 8 September 2017 through 12 September 2017

ER -